Literature DB >> 7695229

Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome.

T Iwatsubo1, D M Mann, A Odaka, N Suzuki, Y Ihara.   

Abstract

The chronological relationship regarding deposition of amyloid beta protein (A beta) species, A beta 40 and A beta 42(43), was investigated in 16 brains from Down syndrome patients aged 31 to 64 years. The frontal cortex was probed with two end-specific monoclonals that recognize A beta 40 or A beta 42(43). All senile plaques detected with an authentic beta monoclonal were also A beta 42(43) positive, but only a varying proportion was A beta 40 positive. In young (< or = 50 years old) brains there were many A beta 42(43)-positive, A beta 40-negative diffuse plaques, but only few A beta 40-positive senile plaques (mean, 6.3% of total number of senile plaques). The 2 youngest Down syndrome brains showed only diffuse plaques that were all A beta 42(43) positive but A beta 40 negative. Old (> 50 years old) brains contained many mature senile plaques with amyloid cores in addition to diffuse and immature plaques and the proportion of A beta 40-positive senile plaques was increased (mean, 42% of total). Cerebral amyloid angiopathy was more abundant in old Down syndrome brains and was positive for both A beta 40 and A beta 42(43). In cerebral amyloid angiopathy, A beta 40 predominated over A beta 42(43) in both staining intensity and number of positive vessels. These results indicate that (1) the A beta species initially deposited in the brain as senile plaques is A beta 42(43) and A beta 40 only appears a decade later, and (2) in cerebral amyloid angiopathy A beta 40 appears as early as A beta 42(43).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7695229     DOI: 10.1002/ana.410370305

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  86 in total

1.  Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption.

Authors:  C M Yip; J McLaurin
Journal:  Biophys J       Date:  2001-03       Impact factor: 4.033

2.  Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease.

Authors:  W Xia; J Zhang; R Perez; E H Koo; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons.

Authors:  J Van Dorpe; L Smeijers; I Dewachter; D Nuyens; K Spittaels; C Van Den Haute; M Mercken; D Moechars; I Laenen; C Kuiperi; K Bruynseels; I Tesseur; R Loos; H Vanderstichele; F Checler; R Sciot; F Van Leuven
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

4.  Observations in APP bitransgenic mice suggest that diffuse and compact plaques form via independent processes in Alzheimer's disease.

Authors:  Anna Lord; Ola Philipson; Therése Klingstedt; Gunilla Westermark; Per Hammarström; K Peter R Nilsson; Lars N G Nilsson
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

5.  C terminus of presenilin is required for overproduction of amyloidogenic Abeta42 through stabilization and endoproteolysis of presenilin.

Authors:  T Tomita; R Takikawa; A Koyama; Y Morohashi; N Takasugi; T C Saido; K Maruyama; T Iwatsubo
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

6.  On the nucleation of amyloid beta-protein monomer folding.

Authors:  Noel D Lazo; Marianne A Grant; Margaret C Condron; Alan C Rigby; David B Teplow
Journal:  Protein Sci       Date:  2005-06       Impact factor: 6.725

Review 7.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

8.  Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.

Authors:  Bing Gong; Ottavio V Vitolo; Fabrizio Trinchese; Shumin Liu; Michael Shelanski; Ottavio Arancio
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

9.  Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice.

Authors:  Bao-Xi Qu; Qun Xiang; Liping Li; Stephen Albert Johnston; Linda S Hynan; Roger N Rosenberg
Journal:  J Neurol Sci       Date:  2007-06-15       Impact factor: 3.181

10.  Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric.

Authors:  Samir Kumar-Singh; Patrick Cras; Rong Wang; John M Kros; Johan van Swieten; Ursula Lübke; Chantal Ceuterick; Sally Serneels; Krist'l Vennekens; Jean-Pierre Timmermans; Eric Van Marck; Jean-Jacques Martin; Cornelia M van Duijn; Christine Van Broeckhoven
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.